New approaches to inhibiting platelets and coagulation

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Ischemic heart disease and stroke are leading global causes of death and disability.
• Thrombotic events stem from platelet activation and coagulation cascade, often linked to atherosclerosis.
• Current therapeutic strategies involve antiplatelet and anticoagulant medications.

Purpose of the Study:

• To review the pharmacology and clinical evidence of traditional and novel antiplatelet and anticoagulant therapies.
• To discuss the evolving landscape of treatments for preventing thrombotic events.
• To address controversies surrounding aspirin use and optimal dosing.

Main Methods:

• Literature review of pharmacological data and clinical trial evidence.
• Analysis of current and emerging antiplatelet agents, including P2Y12 inhibitors.
• Evaluation of advancements in oral anticoagulation, such as direct thrombin and factor Xa inhibitors.

Main Results:

• Aspirin's role in primary prevention remains debated, with ongoing discussion on secondary prevention doses.
• New oral and intravenous P2Y12 inhibitors are transforming antiplatelet therapy.
• Direct thrombin and factor Xa inhibitors offer effective oral anticoagulation without routine monitoring.

Conclusions:

• The field of antiplatelet and anticoagulant therapy is rapidly advancing.
• Novel agents provide new options for managing and preventing thrombotic cardiovascular and cerebrovascular events.
• Evidence supports the expanding use of newer agents with improved safety and efficacy profiles.